Janux Therapeutics (NASDAQ:JANX) Shares Gap Down – What’s Next?

Janux Therapeutics, Inc. (NASDAQ:JANX) gapped down before the market opened on Wednesday . The stock had previously closed at $15.24, but opened at $14.68. Janux Therapeutics shares last traded at $14.77, with a volume of 182,233 shares.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Guggenheim dropped their price target on Janux Therapeutics from $72.00 to $68.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Wall Street Zen upgraded Janux Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, April 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Janux Therapeutics in a research report on Thursday, January 22nd. Barclays dropped their price objective on Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating for the company in a research report on Wednesday, December 17th. Finally, Clear Str cut Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 20th. Ten equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $53.09.

Janux Therapeutics Trading Down 3.1%

The business has a 50 day simple moving average of $13.81 and a 200-day simple moving average of $18.51. The stock has a market capitalization of $898.22 million, a price-to-earnings ratio of -8.06 and a beta of 2.82.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.14. The business had revenue of $7.88 million during the quarter, compared to analyst estimates of $0.08 million. Research analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Institutional Trading of Janux Therapeutics

A number of hedge funds have recently added to or reduced their stakes in JANX. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Janux Therapeutics in the 4th quarter valued at about $34,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Janux Therapeutics in the 4th quarter valued at about $51,000. Osaic Holdings Inc. lifted its stake in shares of Janux Therapeutics by 704.6% in the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after purchasing an additional 3,037 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Janux Therapeutics by 175.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after purchasing an additional 2,502 shares in the last quarter. Finally, Winthrop Capital Management LLC acquired a new position in shares of Janux Therapeutics in the 3rd quarter valued at about $106,000. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.